2023
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy
Voruganti T, Soulos P, Mamtani R, Presley C, Gross C. Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncology 2023, 9: 334-341. PMID: 36701150, PMCID: PMC9880865, DOI: 10.1001/jamaoncol.2022.6901.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerImmune checkpoint inhibitorsUse of ICIsPatients 75 yearsCell lung cancerDrug Administration approvalCohort studyOlder patientsLung cancerAdministration approvalUS FoodAdoption of immunotherapyMedian overall survivalCancer-directed therapySubstantial survival benefitFirst US FoodCheckpoint inhibitorsStage IIIBClinical characteristicsICI useMedian survivalOverall survivalSurvival benefitSurvival gain
2004
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy VH, Krumholz HM, Gross CP. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. JAMA 2004, 291: 2720-2726. PMID: 15187053, DOI: 10.1001/jama.291.22.2720.Peer-Reviewed Original ResearchConceptsCancer trialsCancer clinical trialsClinical trialsTrial participantsEnrollment fractionWhite patientsAge groupsCross-sectional population-based analysisProstate cancer clinical trialsCancer research participationCancer trial participantsColorectal cancer trialsPatients 75 yearsIncident cancer patientsLung cancer trialsPopulation-based analysisRelative risk ratiosAge-based disparitiesYears of ageNational Cancer InstituteLogistic regression modelsLittle recent informationTrial enrolleesYounger patientsPatient group